Extracorporeal Membrane Oxygenation in Children With Cancer or Hematopoietic Cell Transplantation: Single-Center Experience in 20 Consecutive Patients

Potratz, Jenny; Guddorf, Sarah; Ahlmann, Martina; Tekaat, Maria; Omran, Heymut; Masjosthusmann, Katja; Groll, Andreas H.

doi:10.3389/fonc.2021.664928

Cited by 4 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent reports have indicated an ECMO success rate in pediatric settings of 20%–40% [ 12 , 13 ]. In the present study, we observed ICU and hospital survival rates of 29% and 24%, respectively, similar to previously reported survival rates [ 14 - 17 ]. In a previous analysis conducted at a single institution in South Korea, the survival rate among 15 adult patients with hematological malignancies and receiving ECMO was 0% [ 18 ].…”

Section: Discussionsupporting

confidence: 92%

Outcomes of extracorporeal membrane oxygenation support in pediatric hemato-oncology patients

An,

Kang,

Park

2024

ACC

View full text Add to dashboard Cite

Background: In this study, we reviewed the outcomes of pediatric patients with malignancies who underwent hematopoietic stem cell transplantation (HSCT) and extracorporeal membrane oxygenation (ECMO).Methods: We retrospectively analyzed the records of pediatric hemato-oncology patients treated with chemotherapy or HSCT and who received ECMO in the pediatric intensive care unit (PICU) at Seoul National University Children’s Hospital from January 2012 to December 2020.Results: Over a 9-year period, 21 patients (14 males and 7 females) received ECMO at a single pediatric institute; 10 patients (48%) received veno-arterial (VA) ECMO for septic shock (n=5), acute respiratory distress syndrome (ARDS) (n=3), stress-induced myopathy (n=1), or hepatopulmonary syndrome (n=1); and 11 patients (52%) received veno-venous (VV) ECMO for ARDS due to pneumocystis pneumonia (n=1), air leak (n=3), influenza (n=1), pulmonary hemorrhage (n=1), or unknown etiology (n=5). All patients received chemotherapy; 9 received anthracycline drugs and 14 (67%) underwent HSCT. Thirteen patients (62%) were diagnosed with malignancies and 8 (38%) were diagnosed with non-malignant disease. Among the 21 patients, 6 (29%) survived ECMO in the PICU and 5 (24%) survived to hospital discharge. Among patients treated for septic shock, 3 of 5 patients (60%) who underwent ECMO and 5 of 10 patients (50%) who underwent VA ECMO survived. However, all the patients who underwent VA ECMO or VV ECMO for ARDS died. Conclusions: ECMO is a feasible treatment option for respiratory or heart failure in pediatric patients receiving chemotherapy or undergoing HSCT.

show abstract

Section: Discussionsupporting

confidence: 92%

Outcomes of extracorporeal membrane oxygenation support in pediatric hemato-oncology patients

An,

Kang,

Park

2024

ACC

View full text Add to dashboard Cite

show abstract

“…Sixty-four manuscripts met search criteria and 24 were included as primary reports of pediatric HCT patients who underwent ECLS. These 24 reports included 11 single case reports (17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27), four single institution case series (28)(29)(30)(31), two multi-institution case series (32,33), and seven registry reports from Extracorporeal Life Support Organization (ELSO), Pediatric Heath Information System (PHIS), and Virtual Pediatric Systems (VPS) (14,15,(34)(35)(36)(37)(38). As patients included in these case reports, series, and registries are variably deidentified, we cannot exclude the possibility of patient overlap in these multiple manuscript formats.…”

Section: Resultsmentioning

confidence: 99%

“…Jensen et al (30) reported a cohort of n = 4 pediatric HCT patients treated with ECLS between 2000 and 2017 with three of the four surviving to hospital discharge. In 2021, Potratz et al (31) and Bridges et al (32) each reported an additional n = 9 children, of whom n = 3 and n = 2 survived, respectively. Di Nardo et al (28) reviewed a single center experience with 10 children, two surviving to hospital discharge.…”

Section: Case Seriesmentioning

confidence: 99%

Candidacy for Extracorporeal Life Support in Children After Hematopoietic Cell Transplantation: A Position Paper From the Pediatric Acute Lung Injury and Sepsis Investigators Network’s Hematopoietic Cell Transplant and Cancer Immunotherapy Subgroup

Zinter

McArthur

Duncan

et al. 2021

Pediatric Critical Care Medicine

View full text Add to dashboard Cite

The last decade has seen improved outcomes for children requiring extracorporeal life support as well as for children undergoing hematopoietic cell transplantation. Thus, given the historically poor survival of hematopoietic cell transplantation patients using extracorporeal life support, the Pediatric Acute Lung Injury and Sepsis Investigators' hematopoietic cell transplantation and cancer immunotherapy subgroup aimed to characterize the utility of extracorporeal life support in facilitating recovery from critical cardiorespiratory illnesses in pediatric hematopoietic cell transplantation patients. DATA SOURCES:All available published data were identified using a set of PubMed search terms for pediatric extracorporeal life support and hematopoietic cell transplantation. STUDY SELECTION:All articles that provided original reports of pediatric hematopoietic cell transplantation patients who underwent extracorporeal life support were included. Sixty-four manuscripts met search criteria. Twenty-four were included as primary reports of pediatric hematopoietic cell transplantation patients who underwent extracorporeal life support (11 were single case reports, four single institution case series, two multi-institution case series, and seven registry reports from Extracorporeal Life Support Organization, Pediatric Heath Information System, and Virtual Pediatric Systems). DATA EXTRACTION:All 24 articles were reviewed by first and last authors and a spread sheet was constructed including sample size, potential biases, and conclusions.DATA SYNTHESIS: Discussions regarding incorporation of available evidence into our clinical practice were held at biannual meetings, as well as through email and virtual meetings. An expert consensus was determined through these discussions and confirmed through a modified Delphi process. CONCLUSIONS:Extracorporeal life support in hematopoietic cell transplantation patients is being used with increasing frequency and potentially improving survival.

show abstract

Extracorporeal membrane oxygenation in patients with hematologic malignancies: a systematic review and meta-analysis

et al. 2022

View full text Add to dashboard Cite

Extracorporeal Membrane Oxygenation in Children With Cancer or Hematopoietic Cell Transplantation: Single-Center Experience in 20 Consecutive Patients

Cited by 4 publications

References 19 publications

Outcomes of extracorporeal membrane oxygenation support in pediatric hemato-oncology patients

Outcomes of extracorporeal membrane oxygenation support in pediatric hemato-oncology patients

Candidacy for Extracorporeal Life Support in Children After Hematopoietic Cell Transplantation: A Position Paper From the Pediatric Acute Lung Injury and Sepsis Investigators Network’s Hematopoietic Cell Transplant and Cancer Immunotherapy Subgroup

Extracorporeal membrane oxygenation in patients with hematologic malignancies: a systematic review and meta-analysis

Contact Info

Product

Resources

About